<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The International <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> Study Group has proposed a consensus classification for lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> are defined as distinct biological entities, based on a combination of morphologic, immunophenotypic, genetic, and clinical features </plain></SENT>
<SENT sid="2" pm="."><plain>Each distinct disease may have a range of histologic grade and clinical <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Although many distinct diseases can now be recognized, three of them (follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>) account for the majority of the cases seen in Europe and the USA </plain></SENT>
<SENT sid="4" pm="."><plain>Recognition of distinct disease entities is essential in order to develop and test effective therapies </plain></SENT>
</text></document>